Peer-Reviewed Publication
Cancers (Basel)2024;16(17)August 31, 2024Journal Article
The RAL Small G Proteins Are Clinically Relevant Targets in Triple Negative Breast Cancer.
David Han1, Jonathan M Spehar1, Dillon S Richardson1, Sumudu Leelananda2, Prathik Chakravarthy1, Samantha Grecco1, Jesse Reardon1, Daniel G Stover3, Chad Bennett4, Gina M Sizemore1, Zaibo Li5, Steffen Lindert6, Steven T Sizemore1
1Department of Radiation Oncology, Arthur G. James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
2Anagenex, 20 Maguire Rd. Suite 302, Lexington, MA 02421, USA.
3Department of Internal Medicine, Arthur G. James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
4Drug Development Institute, Arthur G. James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
5Department of Pathology, Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA.
6Department of Chemistry and Biochemistry, The Ohio State University, Columbus, OH 43210, USA.
Abstract
Breast cancer (BC) is the most frequent cancer and second-leading cause of cancer deaths in women in the United States. While RAS mutations are infrequent in BC, triple-negative (TN) and HER2-positive (HER2+) BC both exhibit increased RAS activity. Here, we tested the RAS effectors RALA and RALB, which are overexpressed in BC, as tractable molecular targets in these subtypes. While analysis of the…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans